NYSE:NUVB

Nuvation Bio Stock Insider Trading

Healthcare > Biotechnology

Buy NUVB

*Your capital is at risk

$4.72

-0.180 (-3.67%)

At Close: Jun 03, 2026

Nuvation Bio Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 16.09. In total, the insiders bought 17.87M and sold 1.85M NUVB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	16.09
● Buy	17.87M shares
● Sell	1.85M shares
84% Buy Activity Strong Negative Correlation
Sell Signal Low Confidence Apr 06, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Cui Xiangmin Director	Director	123 397 Value: $591.1K
May 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Bazemore Robert B Director	Director	123 397 Value: $591.1K
May 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Blickenstaff Kim D Director	Director	123 397 Value: $591.1K
May 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Falberg Kathryn E Director	Director	123 397 Value: $591.1K
May 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Mashal Robert Director	Director	123 397 Value: $591.1K
May 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Vernon W Anthony Director	Director	123 397 Value: $591.1K
Apr 17, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Wentworth Kerry Chief Regulatory Officer	Officer	36 750 Value: $107.7K
Apr 17, 2026 Buy	Class A Common Stock M-Exempt	Wentworth Kerry Chief Regulatory Officer	Officer	36 750 Value: $107.7K
Apr 17, 2026 Sell	Class A Common Stock S-Sale	Wentworth Kerry Chief Regulatory Officer	Officer	36 750 Value: $184.3K
Apr 17, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Liu Dongfang Chief Medical Officer	Officer	50 000 Value: $97.0K
Apr 17, 2026 Buy	Class A Common Stock M-Exempt	Liu Dongfang Chief Medical Officer	Officer	50 000 Value: $97.0K
Apr 17, 2026 Sell	Class A Common Stock S-Sale	Liu Dongfang Chief Medical Officer	Officer	50 000 Value: $251.0K
Apr 06, 2026 Buy	Class A Common Stock M-Exempt	Wentworth Kerry Chief Regulatory Officer	Officer	100 000 Value: $194.0K
Apr 06, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Wentworth Kerry Chief Regulatory Officer	Officer	100 000 Value: $187.0K
Apr 06, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Wentworth Kerry Chief Regulatory Officer	Officer	100 000 Value: $194.0K
Apr 06, 2026 Buy	Class A Common Stock M-Exempt	Wentworth Kerry Chief Regulatory Officer	Officer	100 000 Value: $187.0K
Apr 06, 2026 Sell	Class A Common Stock S-Sale	Wentworth Kerry Chief Regulatory Officer	Officer	200 000 Value: $903.6K
Feb 27, 2026 Buy	Stock Option (Right to Buy) A-Award	Cui Xiangmin Director	Director	76 923 Value: $454.6K
Feb 27, 2026 Buy	Stock Option (Right to Buy) A-Award	Hung David President And CEO	CEO / President	1 995 012 Value: $11.8M
Feb 27, 2026 Buy	Stock Option (Right to Buy) A-Award	Cui Xiangmin Director	Director	74 813 Value: $442.1K
Feb 27, 2026 Buy	Stock Option (Right to Buy) A-Award	Markel Stacy Chief People Officer	Officer	748 130 Value: $4.42M
Feb 27, 2026 Buy	Class A Common Stock A-Award	Makunje Moses See Remarks	Officer	50 761 Value: $300.0K
Feb 27, 2026 Buy	Stock Option (Right to Buy) A-Award	Makunje Moses See Remarks	Officer	224 439 Value: $1.33M
Feb 27, 2026 Buy	Stock Option (Right to Buy) A-Award	Liu Dongfang Chief Medical Officer	Officer	748 130 Value: $4.42M
Feb 27, 2026 Buy	Stock Option (Right to Buy) A-Award	Wentworth Kerry Chief Regulatory Officer	Officer	748 130 Value: $4.42M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT NUVATION BIO INC.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiat...

Read Full Profile Here